myeloma

Key Takeaways on Evolving Treatment Landscape in Multiple Myeloma

Cancer Network - 18 Apr 2024
Key Takeaways on Evolving Treatment Landscape in Multiple Myeloma ...

Myeloma Expert: Earlier Use of Bispecifics Can Improve Patient Outcomes

Drug Topics - 18 Apr 2024
Myeloma Expert: Earlier Use of Bispecifics Can Improve Patient Outcomes ...

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against ...

Nature.com - 15 Apr 2024
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against ... ...

New Agent Shows Early Promise in Triple-Class Refractory MM

Medscape - 17 Apr 2024
New Agent Shows Early Promise in Triple-Class Refractory MM ...

Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma

OncLive - 18 Apr 2024
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma ...

J&J reports $133M in sales for new multiple myeloma med Tecvayli

FiercePharma - 16 Apr 2024
J&J reports $133M in sales for new multiple myeloma med Tecvayli ...

Daratumumab Plus Standard Therapy for Multiple Myeloma

National Cancer Institute (.gov) - 19 Jan 2024
Daratumumab Plus Standard Therapy for Multiple Myeloma ...

Banerjee Discusses Emerging Research for CAR T in Multiple Myeloma

Targeted Oncology - 14 Apr 2024
Banerjee Discusses Emerging Research for CAR T in Multiple Myeloma ...

What Is Multiple Myeloma?

Mass General Brigham - 02 Jan 2024
What Is Multiple Myeloma? ...

CAR T-cell therapy OK'd as second-line multiple myeloma treatment

Myeloma Research News - 16 Apr 2024
CAR T-cell therapy OK'd as second-line multiple myeloma treatment ...

Rheological properties of blood in multiple myeloma patients | Scientific Reports

Nature.com - 21 Feb 2024
Rheological properties of blood in multiple myeloma patients | Scientific Reports ...

ODAC Approves MRD End Point in Multiple Myeloma Trials

Cancer Network - 12 Apr 2024
ODAC Approves MRD End Point in Multiple Myeloma Trials ...

As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake

FiercePharma - 09 Apr 2024
As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake ...

A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death | Blood Cancer Journal

Nature.com - 09 Apr 2024
A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death | Blood Cancer Journal ...

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide | Blood Cancer Journal

Nature.com - 26 Mar 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide | Blood Cancer Journal ...

The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease

Nature.com - 19 Mar 2024
The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease ...

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study | Blood Cancer Journal

Nature.com - 05 Mar 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study | Blood Cancer Journal ...

Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review | Blood Cancer Journal

Nature.com - 25 Jan 2024
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review | Blood Cancer Journal ...

Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA ...

Nature.com - 06 Mar 2024
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA ... ...